Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management-Reference-Cited by-同舟云学术

Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management

Published:2014-10-15 Issue:3 Volume:168 Page:317-327
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Nocturne Gaetane¹,Mariette Xavier¹²

Affiliation:

1. INSERM U1012; Paris-Sud University; Le Kremlin-Bicêtre France

2. Department of Rheumatology; Hopitaux Universitaires Paris-Sud; Paris-Sud University; Assistance Publique des Hopitaux de Paris; Le Kremlin-Bicêtre France

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13192/fullpdf

Reference93 articles.

1. Autoantibodies associated with RNA are more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE;Ahlin;Lupus,2012

2. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003;Alamanos;Rheumatology (Oxford),2006

3. Human B lymphoma cell line producing B cell growth factor;Ambrus;The Journal of Clinical Investigation,1985

4. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren's syndrome;Amft;Arthritis and Rheumatism,2001

5. Clinicopathological factors relating malignant lymphoma with Sjogren's syndrome;Anaya;Seminars in Arthritis and Rheumatism,1996

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenesis of Sjögren syndrome;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Precision medicine in Sjögren's disease;The Lancet Rheumatology;2024-09

3. Identification and Validation of IFI44 as a Novel Biomarker for Primary Sjögren’s Syndrome;Journal of Inflammation Research;2024-08

4. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study;The Lancet;2024-08

5. Maladies auto-immunes systémiques;Revue du Rhumatisme;2024-08